



CURRICULUM VITAE

Name : Teerha Piratvisuth MD.

Date of birth : 02 January 1960

Address : NKC Institute of Gastroenterology and Hepatology
8th floor Charlermprabaree Building
Department of Medicine
Songklanagarind Hospital, Prince of Songkla University
Hat Yai, Songkhla 90110
Thailand.
Tel: +66-74-451965-9 Ext 115 , Fax: +66-74-429436
E-mail: teerha.p@psu.ac.th

Education

1985 - First Class Honor in General Medicine, (MD), Prince of Songkhla University Thailand.

Postgraduate Training

- 1996 - Thaiboard in Gastroenterology, Thailand.
- 1995 - Clinical Fellow in Hepatology and Endoscopy, The University of Texas-Houston Medical School, USA.

- 1993 – 1994 - Clinical Fellow in Hepatology, King’s College School of Medicine & Dentistry, London, UK.
- 1989 - Certificate of Thaiboard in Internal Medicine, Thailand.

Appointment

1. Associate Professor of Medicine, Prince of Songkla University, Hat Yai, Thailand
2. Vice Dean for International Affair, Faculty of Medicine, Prince of Songkla University, Hat Yai, Thailand.
3. Director of NKC Institute of Gastroenterology and Hepatology Songklanagarind Hospital, Hat Yai, Thailand
4. **President of Thai Association for the Study of the Liver (2011-2012)**
5. President of Asia Pacific Association for the Study of the Liver Disease 2011 (APASL2011)
6. **Vice President of Asia Pacific Digestive Week 2012 (APDW 2012)**
7. Steering Committee of APASL 2010 – present
8. Chairman of Scientific for Thai Association for the Study of the Liver Disease (2013-2016)
9. Chairman of Fund Raising for Gastroenterological Association of Thailand (2012-2016)
10. Chairman of Scientific for 4th ASEAN Perspective in Liver Disease (2016)

11. A committee of Thai Liver Foundation
12. The editorial board of *Hepatology*, *Korean Journal of Gastroenterology*, *Chinese Journal of Infectious Disease* and *American Journal of Gastroenterology* and is a reviewer for *Journal of Gastroenterology and Hepatology*, *Journal of Alimentary Pharmacology and Therapeutics*, *Journal of Hepatology*, *Hepatology*, *Liver International*, *Hepatology International*, *Journal of Viral Hepatitis* and *Antiviral Therapy*, *Journal of Antimicrobial chemotherapy*
13. Council member of IC-HEP Asia Pacific 2013-present

Membership

1. - Royal College of Physicians of Thailand.
2. - Gastroenterological Association of Thailand.
3. - Liver Society of Thailand.
4. - APASL

Publications

- 1 Piratvisuth T. Approach to Dyspepsia. *Ambulatory Medicine*. 1991; 1-9.
- 2 Piratvisuth T, Ovarlarnporn B. Biliary Stent: A Preliminary Report of Experience in Varsity Biliary Diseases. *Songkhla Med J* 1992; 10 (2): 147-50.
- 3 Piratvisuth T, Dunne B, Williams R and Tredger JM. Amlodipine Improves Hepatic Hemodynamic and Metabolic Function in Isolated Perfused Rat Liver After Sequential Cold and Warm Ischemia. *Transplantation* 1995; 60 (1) 23-8.
- 4 Piratvisuth T, Tredger JM, Hayllar KA, Williams R. Contribution of True Cold and Rewarming Ischemia Times to Factor Determining Outcome After Orthotopic Liver Transplantation. *Liver Transplantation and Surgery* 1995; 1(5): 296-301.
- 5 Chayakul P, Piratvisuth T, et al. Capillaritis : Reported 2 Cases From Southern Thailand. *J Infect Dis Antimicrob Agents* 1988; 5(4): 187-90.
- 6 Ovarlarnporn B, Piratvisuth T, et al. Therapeutic Endoscopy of Biliary Tract: The Experience of Songkhlanagarind Hospital. *The Thai Journal of Surgery* 1991; 12: 7-11.
- 7 Piratvisuth T. Hepatitis C. *HEPATITIS C*. 1st edition Bangkok. 1996; 1-27.
- 8 Dunne JB, Piratvisuth T, Williams R and Tredger JM. Treatment of Experimental Ischemia/Reperfusion Injury with S-adenosylmethionine. *Transplantation*. 1997; 3(4):1-7.
- 9 Piratvisuth T, Ovarlarnporn B. What's New in Viral Hepatitis? *Medicine I*. Bangkok. 1997; 57-96.
- 10 Piratvisuth T. Hepatitis B. 1st edition. Bangkok. 1997; 1-40.
- 11 Piratvisuth T. Liver Transplantation for Hepatitis B Virus Related Liver Disease. *International symposium on Viral Hepatitis and Perspectives from The Asean Region Bangkok* , Sep 1997; 31-35.
- 12 Piratvisuth T, Sithinamsuwan P, Kanjanabuch T, Tongyoo S. Idiopathic Portal Hypertension: Case Report and Review. *Annual Meeting of The Gastroenterological Association of Thailand, Bangkok*, Jan.1998.
- 13 Piratvisuth T. Liver Disease In Pregnancy. *The Annual Scientific Meeting of The Gastroenterological Association of Thailand, Phitsanuloke*, Nov 1998; 153-61.

- 14 Piratvisuth T, Siripaitoon P, Sriplug H and Ovartharnporn B. Findings and Benefit of Liver Biopsies in 46 Patient Infected with Human Immunodeficiency Virus [HIV]. *J Gastroenterol Hepatol*, Feb.1999; 14(2):146-9.
- 15 Piratvisuth T. *Hepatitis B & Hepatitis C*. 1st ed. Bangkok. C&S Printing. 1999; 1-87.
- 16 Sooklim K, Sriplung H, Piratvisuth T. Histologic Subtypes of Hepatocellular Carcinoma in the Southern Thai Population. *Asian Pacific Journal of Cancer Prevention*; 2003: 4, 1-5.
- 17 Mohamed R, Desmond P, Suh DJ, Amarapurkar D, Gane E, Guangbi Y, Hou JL, Jafri W, Lai CL, Lee CH, Lee SD, Lim SG, Guan R, Phiet PH, Piratvisuth T, et al. Practical Difficulties in the Management of Hepatitis B in the Asia-Pacific Region. *J Gastroenterol Hepatol*. 2004 Sep; 19(9):958-69.
- 18 Marcellin P, Lau G.K.K., Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T. et al. Peginterferon alfa-2a Alone, Lamivudine Alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. *N Engl J Med*. 2004 Sep 16;351(12):1206-17.
- 19 Lau G.K.K, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N. Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B. *N Engl J Med*. 2005 Jun 30;352(6):2682-95.
- 20 Yun-Fan Liaw, Nancy Leung, Richard Guan, George K.K. Lau, Ismail Merican, Geoff McCaughan, Edward Gane, Jia-Horng Kao, and Masao Omata for the Asian-Pacific consensus update working party on chronic hepatitis B (Piratvisuth T). et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. *Liver Int*. 2005 Jun;25(3):472-89.
- 21 Bonino F, Marcellin P, Lau G K K, Hadziyannis S, Jin R, Piratvisuth T, et al. Predicting response to peginterferon alfa-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. *Gut* 2007; 56(5): 699-705.
- 22 McCaughan G.W, Omata M, Amarapurkar D, Chutaputti A, Dore G, Gane E, Guan R, Hamid S.S., Hardikar W, Hui C.K, Jafri W, Jia J.-D., Lai M.-Y., Wei L., Leung N, Piratvisuth T., et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. *J Gastroenterol Hepatol*. 2007; 22(5): 615-633
- 23 Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban–Mur R, Gane EJ, Jacobson IM, Lim SG, Naoumov N, Marcellin P, Piratvisuth T, et al. Report of an International Workshop: Roadmap for Management of Patients Receiving Oral Therapy for Chronic Hepatitis B. *Clin Gastroenterol Hepatol*. Aug 2007; 5(8): 890-897
- 24 Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, Luo KX, Paik SW, Liaw YF, Button P, Popescu M. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for

- HBeAg-positive chronic hepatitis B. *Hepatology*. Feb 2008; 47(2):428-434
- 25 Piratvisuth T. Reviews for APASL guidelines: Immunomodulator therapy of chronic hepatitis B. *Hepatology Int*. 2008; 2 (2): 140-146.
- 26 Piratvisuth T, Lau GKK, Chao YC, Jin R, Chutaputti A, Zhang QB, Tanwandee T, Button P, Popescu M. Sustained response to Peginterferon alfa-2a (40 KD) with or without Lamivudine in Asian Patients with HBeAg-positive and HBeAg-negative Chronic Hepatitis B. *Hepatology Int*. 2008; 2: 102-110.
- 27 Marcellin P, Lau GK, Zeuzem S, Heathcote EJ, Pockros PJ, Reddy KR, Piratvisuth T, et al. Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. *Liver Int*. 2008 Apr;28(4):477-85.
- 28 Liaw YF, Leung N, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. *Hepatology International*. Published online. 10 May 2008.
- 29 Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T. et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alfa-2a. *Gastroenterology*. 2009 Jun;136(7):2169-2179.e1-4. Epub 2009 Mar 19.
- 30 Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T. et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. *Hepatology*. 2009 Apr;49(4):1141-50.
- 31 You J, Zhuang L, Zhang YF, Chen HY, Sriplung H, Geater A, Chongsuvivatwong V, Piratvisuth T, et al. Peripheral T-lymphocyte subpopulations in different clinical stages of chronic HBV infection correlate with HBV load. *World J Gastroenterol*. 2009 Jul 21;15(27):3382-93.
- 32 Buster EH, Hansen BE, Lau GK, Piratvisuth T, et al. Factors that Predict Response of Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B to Peginterferon-alpha. *Gastroenterology*. 2009 Dec;137(6):2002-9. Epub 2009 Sep 6.
- 33 Marcellin P, Sung J, Piratvisuth T. Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon. *Liver Int*. 2010 May;30(5):657-68. Epub 2010 Feb 15.
- 34 Ahn SH, Chan HL, Chen PJ, Cheng J, Goenka MK, Hou J, Lim SG, Omata M, Piratvisuth T, et al. Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. *Hepatology Int*. 2010 Feb 20;4(1):386-395.
- 35 Lui YY, Tsoi KK, Wong VW, Kao JH, Hou JL, Teo EK, Mohamed R, Piratvisuth T, et al. Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. *Antivir Ther*. 2010;15(2):145-55.
- 36 Sung JJ, Amarapurkar D, Chan HL, Cheng J, Kao JH, Han KH, Piratvisuth T. Treatment of chronic hepatitis B in Asia-Pacific countries: is the Asia-Pacific consensus statement being followed? *Antivir Ther*. 2010;15(4):607-16.
- 37 Bonino F, Piratvisuth T, Brunetto MR, Liaw YF. Diagnostic markers of chronic hepatitis B infection and disease. *Antivir Ther*. 2010;15 Suppl 3:35-44.
- 38 Piratvisuth T, Marcellin P. et al. Further analysis is required to identify an

- early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen-positive patients. *Hepatology*. 2011 Mar;53(3):1054-5
- 39 Netinatsunton N, Attasaranya S, Ovarlarnporn B, Sangnil S, Boonviriyaya S, Piratvisuth T. The value of Carlsson-dent questionnaire in diagnosis of gastroesophageal reflux disease in area with low prevalence of gastroesophageal reflux disease. *J Neurogastroenterol Motil*. 2011 Apr;17(2):164-8.
- 40 Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. *Liver Int*. 2011 Jul;31 Suppl 2:61-80.
- 41 Piratvisuth T, Marcellin P, Popescu M, et al. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. *Hepatology*. 2011 Jun 24. [Epub ahead of print]
- 42 Chan HL, Thompson A, Martinot-Peignoux M, Piratvisuth T, et al. Hepatitis B surface antigen quantification: Why and how to use it in 2011 - A core group report. *J Hepatol*. 2011 Jun 28. [Epub ahead of print]
- 43 Ahn SH, Kweon YO, Paik SW, Sohn JH, Lee KS, Kim DJ, Piratvisuth T, et al. Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B. *Hepatology*. 2011 Oct 12. [Epub ahead of print]
- 44 Liaw YF, Jia JD, Chan HL, Han KH, Tanwandee T, Chuang WL, Tan DM, Chen XY, Gane E, Piratvisuth T, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. *Hepatology*. 2011 Nov; 54(5):1591-9.
- 45 Attasaranya S, Netinasunton N, Jongboonyanuparp T, Sottisuporn J, Witeerungrot T, Pirathvisuth T, et al. The Spectrum of Endoscopic Ultrasound Intervention in Biliary Diseases: A Single Center's Experience in 31 Cases. *Gastroenterol Res Pract*. 2012; 2012: 680753.
- 46 Pianko S; Zeuzem S.; Chuang WL.;...(Piratvisuth T.) et al. Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3. *J Viral Hep*. SEP 2012; 19 (9): 623-634.
- 47 Chan HLY, Chen YC, Gane EJ;...(Piratvisuth T.) et al. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis. *J Viral Hep* Oct 2012; 19(10): 732-743
- 48 Piratvisuth T. Viral hepatitis C: Asia Pacific perspectives and guidelines. *J Gastroenterol Hepatol*. Dec 2012; 27 Suppl: 5: 29-30.
- 49 Piratvisuth T. Optimal management of HBV infection during pregnancy of HBV infection. *Liver Int*. Feb 2013; 33 Suppl 1: 188-194.
- 50 McGowan CE, Monis A, Bacon BR, (Piratvisuth T.) et al. A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care. *Hepatology*. 2013 Jan 12. doi: 10.1002/hep.26246.
- 51 Piratvisuth T, Komolmit P, Tanwandee T. et al. 52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B. *PLOS ONE*. Feb 2013; 8 (2): e54279
- 52 Foster GR, Zeuzem S, Pianko S,(Piratvisuth T.) et al., Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin. *J Viral Hepat*. 2013 Apr;20(4):e115-23.
- 53 Sonneveld MJ, Hansen BE, (Piratvisuth T) et al., Response-guided peginterferon therapy in HBeAg-positive chronic hepatitis B using serum

- hepatitis B surface antigen levels. *Hepatology*. 2013 Sep;58(3):872-80.
- 54 McGowan, CE, Monis A, Bacon BR..., (Piratvisuth T.) et al. A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care. *Hepatology*. 2013; 57(4): 1325-1332 DOI: 10.1002/hep.26246
- Treepasertsuk S, Tanwandee T, Piratvisuth T. Natural history, outcome, and sustainability of treatment response in chronic viral hepatitis B: Thai multicenter study. *Asian Biomedicine*. 2013;7(5), pp. 599-607
- 55 Charatcharoenwitthaya P, (Piratvisuth T.) Baseline and on-treatment predictors of chronic hepatitis B patients receiving pegylated interferon therapy in Asia. *Curr Hepatitis Rep* (2013) 12(3):165–173.
- 56 Dan YY, Wong JB, Hamid SS,...(Piratvisuth T) Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries. *Hepato Int*. 2014 July 8(3), 382-394
- 57 Thongsawat S, Piratvisuth T, Pramoolsinsap C, et al. Resource utilization and direct medical costs of chronic hepatitis C in Thailand: A heavy but manageable economic burden. *Value in Health Regional Issues*. May 2014; 3(1): 12-18
- 58 Tangpradabkiet W, Praneenararat S, Chamroonkul N,... (Piratvisuth T.) Influence of Meal Intake on Liver Stiffness in Patients with Chronic Hepatitis B and C. *J Med Association Thailand*. Oct 2014 97(10): 1033-1039.
- 59 Praneenararat S, Chamroonkul N, Sripongpun P,... (Piratvisuth T.) HBV DNA level to predict liver fibrosis in HBeAg negative chronic hepatitis B patients with biopsy indication. *BMC Gastroenterol*. 2014 Dec 19;14(1):218. [Epub ahead of print]
- 60 Colvin RA, Tanwandee T, Piratvisuth T, et al. Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis B infection. *J Gastroenterol Hepatol*. 2015 Jan;30(1):184-91
- 61 Deray G, Buti M, Gane E, ,... (Piratvisuth T.) Hepatitis B Virus Infection and the Kidney: Renal Abnormalities in HBV Patients, Antiviral Drugs Handling, and Specific Follow-Up. *Advances Hepatol*. 2015 (2015), Article ID 596829, 11 pages
- 62 Lim SG, Amarapurkar DN, Chan HLY,... (Piratvisuth T.) Reimbursement policies in the Asia-Pacific for chronic hepatitis B. *Hepatology International* Jan 2015; 9(1): pp 43-51.
- 63 Pawlotsky JM, Flisiak R, Sarin SK,... (Piratvisuth T.) Alisporivir plus ribavirin, interferon-free or in combination with peg-interferon, for HCV genotype 2 or 3 infection. *Hepatology*. 2015 Jun 27. doi: 10.1002/hep.27960.
- 64 Zeuzem S, Flisiak R, Vierling JM,.. (Piratvisuth T.) Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II). *Aliment Pharmacol Ther*. 2015 Oct;42(7):829-844.
- 65 Sarin SK, Kumar M, Lau GK.... (Piratvisuth T.) Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. *Hepato Int*. 2016 Jan;10(1):1-98.
- 66 Charatcharoenwitthaya P, Sukeepaisarnjaroen W, Piratvisuth T, et al. Treatment outcomes and validation of the stopping rule for response to peginterferon in chronic hepatitis B: A Thai nationwide cohort study. *J Gastroenterol Hepatol*. 2016 Mar 21. doi: 10.1111/jgh.13378.
- 67 Piratvisuth T, Han GR, Pol S, et al. Comprehensive review of telbivudine in pregnant women with chronic hepatitis B. *World J Hepatol*. Mar 2016; 8(9):

- 452-460.
- 68 Netinatsunton N, Attasaranya S, Sottisuporn J, (Piratvisuth T.) Comparing cost-effectiveness between endoscopic ultrasound and endoscopic retrograde cholangiopancreatography in diagnosis of common bile duct stone in patients with predefined risks: A study from a developing country. *Endosc Ultrasound*. 2016 May-Jun;5(3):165-72.
- 69 Piratvisuth T, Komolmit P, Chan HL., et al. Efficacy of telbivudine with Conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategy. *Drugs Context*. 2016 Apr 22;5:212294.
- 70 Lertpipommetha K, Tubtawee T, Piratvisuth T, et al. Comparison between Computer Tomography and Magnetic Resonance Imaging in the Diagnosis of Small Hepatocellular Carcinoma. *Asian Pac J Cancer Prev*. 2016 Nov 1;17(11):4805-4811.
- 71 Lim SG, Aghemo A, Chen PJ, (Piratvisuth T.) Management of hepatitis C virus infection in the Asia-Pacific region: an update. *The Lancet Gastroenterology & Hepatology*. Jan 2017; 2(1),p52-62.
- 72 Sripongpun P, Attasaranya S, Chamroonkul N, (Piratvisuth T.) Simple Clinical Score to Predict 24-Week Survival Times in Patients with Inoperable Malignant Distal Biliary Obstruction as a Tool for Selecting Palliative Metallic or Plastic Stents. *J Gastrointest Cancer*. 2017 Jan 17. doi: 10.1007/s12029-017-9918-9.